Focus: Erasca is a public oncology-focused biotech company headquartered in San Diego developing targeted cancer therapies, primarily small-molecule kinase inhibitors for solid tumors and hematologic malignancies. The company operates as a clinical-stage player with a diversified pipeline and recent Big Pharma partnership validation.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
Erasca is a suitable choice for early-to-mid career oncology scientists or clinical developers seeking hands-on pipeline work and partnership exposure, but financial runway and minimal hiring suggest career stability risks without near-term clinical catalysts or capital raises.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Erasca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Erasca's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Does Litigation Over ERAS-0015 and Big Capital Raise Reshape The Bull Case For Erasca (ERAS)? - simplywall.st
Does Litigation Over ERAS-0015 and Big Capital Raise Reshape The Bull Case For Erasca (ERAS)? simplywall.st
Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost - GlobeNewswire
Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost GlobeNewswire
The Bull Case For Erasca (ERAS) Could Change Following ERAS-0015 IP Dispute And Fundraising Moves - simplywall.st
The Bull Case For Erasca (ERAS) Could Change Following ERAS-0015 IP Dispute And Fundraising Moves simplywall.st
ERAS stock trades around recent lows as Erasca focuses on clinical pipeline and cash runway after Na - Ad-hoc-news.de
ERAS stock trades around recent lows as Erasca focuses on clinical pipeline and cash runway after Na Ad-hoc-news.de
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Erasca (ERAS) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Erasca (ERAS) The Globe and Mail
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors.
Showing 5 of 8 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo